Under AAAResearchReports.com Microscope: Star Scientific Inc., Pharmacyclics
Inc., Impax Laboratories Inc., and United Therapeutics Corp.
Editor Note: For more information about this release, please scroll to bottom.
LONDON, October 30, 2013
LONDON, October 30, 2013 /PRNewswire/ --
The U.S. equity market posted gains on Tuesday, October 29, 2013, with the S&P
500, the Dow Jones Industrial Average, and the NASDAQ Composite rising 0.56%,
0.72%, and 0.31%, respectively. Shares in the healthcare-drug makers sector
ended on a higher note, tracking gains in the broader market. The major movers
in the sector included Star Scientific Inc. (NASDAQ: STSI), Pharmacyclics Inc.
(NASDAQ: PCYC), Impax Laboratories Inc. (NASDAQ: IPXL), and United
Therapeutics Corporation (NASDAQ: UTHR). AAAResearchReports.com has released
full comprehensive research on STSI, PCYC, IPXL, and UTHR. These free
technical analyses can be downloaded by signing up at:
Star Scientific Inc.'s stock gained 2.14% on Tuesday, ending the day at an
intra-day high of $1.91, after fluctuating between $1.86 and $1.91 during the
trading session. A total of 0.41 million shares were traded, which is below
the daily average volume of 0.86 million. The company's shares have gained
2.69% in the previous three months, compared to a gain of 5.14% in the S&P 500
during the same period. Additionally, Star Scientific Inc.'s stock is trading
above its 200-day moving average of $1.77. A free technical analysis on STSI
available by signing up at:
On Tuesday, Pharmacyclics Inc.'s shares posted gains, ending the day at
intra-day high of $125.09, which is 0.66% higher than the previous day's
closing price of $124.27. The company's shares fluctuated between $122.19 and
$125.09 during the trading session. A total of 0.53 million shares were
traded, which is below the daily average volume of 0.72 million. Pharmacyclics
Inc.'s shares have surged 19.80% in the previous three months, outperforming
the S&P 500, which has gained 5.14% during the same period. Moreover, the
company's stock is trading above its 50-day and 200-day moving averages of
$123.11 and $95.36, respectively. Register today and access free research on
Impax Laboratories Inc.'s shares ended the day 0.34% higher at $20.68, after
oscillating between $20.33 and $20.74 during Tuesday's trading session. A
total of 0.26 million shares were traded, which is below the daily average
volume of 0.42 million. Impax Laboratories Inc.'s stock has gained 1.82% in
the previous one month, underperforming the S&P 500, which has gained 4.74%
during the same period. Further, the company's shares are trading above their
50-day and 200-day moving averages of $20.50 and $19.17, respectively. The
free report on IPXL can be downloaded by signing up now at:
United Therapeutics Corp.'s stock surged 3.73% on Tuesday, hitting a new
52-week high of $87.50. The company's shares finished the day at $86.50 after
vacillating between $83.65 and $87.50 during the trading session. A total of
1.05 million shares were traded, which is significantly above the daily
average volume of 0.45 million. The company's stock has gained 9.88% in the
previous one month and 19.10% in the previous three months, compared to a gain
of 4.74% and 5.14% in the S&P 500 during the respective periods. Furthermore,
United Therapeutics Corp.'s stock is trading above its 50-day and 200-day
moving averages of $78.24 and $67.13, respectively. A free report on UTHR can
be accessed by registering at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE AAA Research Reports
Contact: +1(646)396-9126, Peter F. Jones, email@example.com
Press spacebar to pause and continue. Press esc to stop.